<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920710</url>
  </required_header>
  <id_info>
    <org_study_id>ACTHAR CNS</org_study_id>
    <nct_id>NCT02920710</nct_id>
  </id_info>
  <brief_title>ACTHAR Therapy for Central Nervous System Sarcoidosis</brief_title>
  <official_title>ACTHAR Therapy for Central Nervous System Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need for a more reliable, expeditious therapy that can be used as an alternative&#xD;
      to glucocorticoids in severe Central Nervous System (CNS) sarcoidosis. This study aims to&#xD;
      provide evidence for effectiveness of ACTHAR gel in CNS sarcoidosis, and provide information&#xD;
      about its safety and tolerability&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central nervous system (CNS) involvement is one of the most severe manifestations of&#xD;
      sarcoidosis. Sarcoidosis affecting the leptomeninges, spinal cord, or brain parenchyma&#xD;
      portends a difficult course and frequently results in severe disability or death (1).&#xD;
      Treatment of moderate and severe CNS sarcoidosis typically involves a combination of&#xD;
      corticosteroids and cytotoxic agents such as methotrexate (2). Unfortunately, most response&#xD;
      rates are reportedly only in the 29-38% range for corticosteroids alone, and the effects of&#xD;
      cytotoxic agents in sarcoidosis require up to 6 months to occur. A typical scenario is that&#xD;
      patients are treated for prolonged periods with high dose glucocorticoids with suboptimal&#xD;
      effectiveness despite development of substantial toxicities. Some series report that&#xD;
      cyclophosphamide or infliximab may be beneficial (3), but these approaches are limited by&#xD;
      potentially severe toxicities, loss of effectiveness, or payor constraints.&#xD;
&#xD;
      . ACTHAR is a 39-amino acid peptide natural form of adrenocorticotropin hormone (ACTH) that&#xD;
      was initially approved in 1952 by the FDA. It has since been approved for 19 indications&#xD;
      including respiratory sarcoidosis, multiple sclerosis, and infantile spasms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficulty with recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">November 2, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with clinically significant improvement - successful glucocorticoid tapering.</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinically significant improvement - no need for escalation of other therapy.</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Experimental: H.P. Achtar Gel 80 U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repository Corticotropin Injection</intervention_name>
    <description>Initial treatment with 80 units daily for ten days (induction phase)&#xD;
Maintenance treatment with 80 units twice weekly (maintenance phase)</description>
    <arm_group_label>Experimental: H.P. Achtar Gel 80 U</arm_group_label>
    <other_name>H.P. Acthar Gel</other_name>
    <other_name>ACTH Gel</other_name>
    <other_name>ACTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic&#xD;
             Society/European Thoracic Society/World Association for Sarcoidosis and Other&#xD;
             Granulomatous Disorders)&#xD;
&#xD;
          -  Stable baseline immunosuppressive medications&#xD;
&#xD;
          -  Moderate to severe disease as defined by at least one of the following criteria:&#xD;
&#xD;
               -  Cranial nerve palsy&#xD;
&#xD;
               -  Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda&#xD;
                  equina involvement&#xD;
&#xD;
               -  Dural or leptomeningeal involvement of brain and/or spinal cord&#xD;
&#xD;
               -  Hydrocephalus&#xD;
&#xD;
               -  Seizures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any underlying neurologic disorder that would potentially confound&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  Significant change in corticosteroid dose within the past 4 weeks, or other&#xD;
             immunosuppressive medication within the past 6 months&#xD;
&#xD;
          -  Evidence of current serious infection, or a history of chronic or recurring&#xD;
             infections.&#xD;
&#xD;
          -  Contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar).&#xD;
&#xD;
          -  Allergies to pig-derived proteins&#xD;
&#xD;
          -  Have a history of any opportunistic infection within 6 months prior to screening&#xD;
&#xD;
          -  History of malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Culver, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Main Campus</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

